Join to access to all OVN content. Join for Free

Early release — we’re building this with you. Share your feedback

Oncology Career

Essentials

Curated books, podcasts, and articles — with one concrete move on every card.

Industry & Business Acumen

113 cards on this shelf

Essentials · Article

You may have more relevant experience than you think — if you frame it right.

The Big Idea

The MSL Academy shows how to translate academic and clinical experience into MSL-relevant terms — publishing research, presenting at conferences, and cross-functional collaboration all map directly onto the role.

Why It Matters

Aspiring oncology MSLs often have exactly the right raw experience; naming it in the role's language is what makes hiring managers see the fit.

One Move

List three things you've done — a paper, a talk, a collaboration — and rewrite each in MSL terms.

Essentials · Article

Tailor your resume to the MSL job description — and consider a stepping-stone role to get closer.

The Big Idea

MSL Consultant advises mirroring the exact language of the MSL job description in your resume, keeping it to two ruthless pages of only relevant skills, and considering adjacent roles like medical writing at pharma-facing agencies as a stepping stone.

Why It Matters

Oncology hiring managers scan for fit fast; a tailored resume and a smart stepping-stone role shorten the distance to your first MSL position.

One Move

Rewrite your resume to mirror a real MSL job description's language, cutting anything not relevant to the role.

Essentials · Article

Before you chase the MSL role, make sure you actually understand what the job is.

The Big Idea

The MSL Academy's complete guide stresses understanding the role before pursuing it — many aspiring MSLs don't fully grasp what the job entails, and researching it lets you customize every application to show you do.

Why It Matters

Oncology hiring managers can tell instantly who understands the MSL role and who's chasing a title; genuine understanding shows in every answer.

One Move

Write a one-paragraph description of what an MSL actually does day to day, and check it against real job postings.

Essentials · Book

The standard prep for case interviews — if you're eyeing strategy, commercial, or consulting roles.

The Big Idea

Cosentino's frameworks for cracking the case-style problem-solving interview.

Why It Matters

Pharma strategy, commercial, and consulting-adjacent oncology roles increasingly use case interviews; this is the playbook.

One Move

Time yourself structuring one market-sizing case end to end.

Essentials · Article

Don't just show your data — tell a story with it, so it changes a decision.

The Big Idea

Data-visualization expert Cole Nussbaumer Knaflic argues that presenting data isn't a technical exercise but storytelling: understand your audience and context first, choose a simple effective visual, ruthlessly eliminate clutter (“chartjunk”), use color and size to focus attention on the one thing that matters, and wrap it in a narrative with a clear beginning, middle, and call to action. Simple beats sexy.

Why It Matters

MSLs and medical teams present clinical data constantly; turning a dense slide into one clear, focused story is what moves a KOL or a committee to act.

One Move

Strip your next data slide to one clear message, and use color to highlight only the point that matters.

Essentials · Book

Work with the difficult colleague you can't avoid — when you carry the responsibility but not the authority.

The Big Idea

Gallo maps eight difficult-coworker archetypes — the passive-aggressive peer, the credit-stealer, the insecure boss — with a specific play for each.

Why It Matters

Oncology runs on matrixed teams — medical, commercial, clinical and regulatory all push on the same launch, so you're forever moving people you don't manage.

One Move

Name which archetype your hardest colleague fits, then use Gallo's one tactic for that type this week.

Essentials · Book

Decode why colleagues hear the same message so differently — and flex so yours lands.

The Big Idea

Erikson sorts people into four color-coded communication styles and shows how to adapt to each.

Why It Matters

In oncology you swing between wildly different audiences in a day — a detail-obsessed regulatory reviewer, a big-picture commercial lead, an anxious patient.

One Move

Type the three people you clash with most, and change one thing in how you brief each.

Essentials · Episode

Why social media monitoring is becoming an essential MSL skill.

The Big Idea

Jason Howard explores with Tom Caravela the role of the medical digital lead — social media monitoring, compliance, and how AI and generative tools are enhancing MSL digital engagement.

Why It Matters

HCPs are increasingly active online; oncology MSLs who monitor and engage compliantly extend their reach.

One Move

Set up one simple way to monitor social conversations in your therapeutic area.

Essentials · Article

Medical Affairs is no longer a support function — it's becoming biopharma's third strategic pillar.

The Big Idea

In its widely cited report, McKinsey argues that Medical Affairs is becoming the third strategic pillar of biopharma alongside R&D and Commercial — as the definition of value broadens and companies need credible, non-promotional science and evidence to prove that value to an expanding set of decision-makers.

Why It Matters

For oncology medical-affairs professionals, this reframes the work from a support function to a strategic one — and shows where the career growth and influence are heading.

One Move

Articulate, in one sentence, how your role generates evidence or value the business needs.

Essentials · Article

Knowing how the business works isn't the same as having the judgment to navigate it — and senior roles want the second.

The Big Idea

Rozen separates business acumen (understanding commercial drivers and structure — now table stakes) from strategic judgment (navigating real trade-offs while keeping independent judgment).

Why It Matters

Oncology MA leaders are told to build "business acumen," but what differentiates at senior levels is judgment under trade-offs. This tells you what to really develop.

One Move

Identify one recent decision where you showed judgment, not just business knowledge — and one where you didn't.

Essentials · Article

Why bringing Medical Affairs in early — not late — can redefine the whole drug development journey.

The Big Idea

A model for integrating Medical Affairs early in development, bridging clinical and commercial to align stakeholders, inform study design, and generate evidence that addresses market needs alongside clinical goals.

Why It Matters

For oncology MA professionals, this reframes the function from late-stage support to a strategic driver of development — a more influential, higher-value seat at the table.

One Move

Identify one development decision where MA could add value earlier than it currently does — and make the case to be in that room.

Essentials · Article

Biotech runs on milestone-gated money — and knowing the stage you're in explains everything around you.

The Big Idea

This guide distinguishes early-stage biotech funding (pre-seed, seed, Series A), which focuses on proving the science and team, from growth-stage funding (Series B and beyond), which supports clinical trials and commercialization — with capital released milestone by milestone and investor expectations shifting from promise to hard evidence.

Why It Matters

Understanding how your oncology company is funded — and what milestone unlocks the next round — explains the urgency, priorities, and risk you feel day to day.

One Move

Learn which funding stage your company is at, and what milestone unlocks the next round.

Essentials · Article

Great science stalls without execution — clinical operations is where strategy becomes reality.

The Big Idea

On The Emerging Biotech Leader, host Ramin Farhood and clinical-operations executive Sharon Arnold discuss how clinical operations translates scientific research into the studies and data that bring therapies to patients — and how operational leadership, well beyond trial execution, determines whether innovation actually reaches the clinic.

Why It Matters

In oncology, brilliant science stalls without execution; understanding how clinical operations drives strategy helps every team member see how their work moves a therapy forward.

One Move

Map where Medical Affairs and clinical operations could engage earlier in your program.

Essentials · Article

Real-world evidence increasingly decides which drugs get expanded indications and coverage.

The Big Idea

This analysis shows real-world evidence moving from nice-to-have to decisive: roughly a quarter of recent FDA labeling expansions involved RWE, making the function that generates it central to whether drugs win expanded indications and coverage — and recasting medical affairs as a commercial driver rather than a support role.

Why It Matters

Oncology lives on real-world outcomes beyond the trial; professionals who understand RWE's growing weight can position their work where the business value is concentrating.

One Move

Find one place real-world evidence could strengthen your product's value story.

Essentials · Article

Biotech has no shortage of competing priorities; digital innovation is how leaders move faster on all of them.

The Big Idea

In this Emerging Biotech Leader bonus episode, SSI Strategy explores how biotechs juggle competing priorities — fundraising, manufacturing, trials, clinical strategy, CMC readiness, building a Medical Affairs team — and why capitalizing on digital innovation has become an essential, not optional, lever for moving faster.

Why It Matters

Oncology programs generate enormous data; professionals who grasp how digital tools accelerate development and evidence generation make themselves more valuable to the enterprise.

One Move

Identify one manual process on your team that a digital tool could streamline.

Essentials · Article

Half of physicians want more time with MSLs — double the share who want more time with sales.

The Big Idea

This piece traces how the MSL role evolved from a credible educational counterpart to commercial reps into a strategic, cross-functional driver — and cites striking signals of its value: half of physicians want more time with MSLs (double the share who want more time with commercial reps), and one in three say MSL interactions have changed how they treat patients.

Why It Matters

It's a reminder that your scientific credibility is a measurable business asset — and a case for investing in the depth that makes you the trusted link between science and the clinic.

One Move

Quantify one way your scientific engagement changed a clinical decision or outcome.

Essentials · Article

Only about 1 in 8 drugs that enter clinical trials ever reaches patients — know the gauntlet your work runs.

The Big Idea

This primer lays out the five phases every therapy must clear — discovery and development, preclinical research, clinical trials, regulatory review, and post-market safety monitoring — and the sobering economics behind them: only about 12% of candidates entering clinical development reach approval.

Why It Matters

Knowing exactly where your program sits in the pipeline — and what the next phase demands — is foundational literacy for any oncology career, from the lab to the field.

One Move

Place your current project on the five-phase development map, and learn what the next phase requires.

Essentials · Article

Clinical trials answer “does it work?” — HEOR answers “is it worth paying for?”

The Big Idea

This explainer frames HEOR — health economics and outcomes research — as the strategic intersection of market access, commercialization, and medical affairs: pharmacoeconomic and outcomes data that lets payers judge whether a therapy delivers equal or better outcomes at an acceptable cost, capturing value such as quality of life that clinical-trial endpoints miss.

Why It Matters

In oncology, where therapies are costly and scrutinized, the evidence that proves value to payers is what determines whether patients can actually access a drug.

One Move

Ask your market-access colleagues what evidence payers need for your therapy.

Essentials · Book

CRISPR's promise and peril — from the scientist who invented it.

The Big Idea

Doudna explains the science of CRISPR and wrestles with its ethical stakes.

Why It Matters

As editing enters oncology, understanding both the power and the risks is part of being responsible.

One Move

Form one view on where you'd draw an ethical line on gene editing.

Essentials · Book

The classic survival guide for building a research career.

The Big Idea

Feibelman's candid advice on navigating science careers beyond the degree.

Why It Matters

Many oncology scientists hit the "now what?" wall after the PhD; this maps the next moves.

One Move

Pick one of Feibelman's tips on visibility and do it this month.

Essentials · Book

Prep for advanced oncology nursing certification.

The Big Idea

A focused review resource for APRNs and advanced oncology nurses.

Why It Matters

Advancing your nursing credential opens roles and pay; this is the prep.

One Move

Take one practice section and find your weakest topic.

Essentials · Book

How US healthcare became big business — and what it costs patients.

The Big Idea

Rosenthal dissects the economics that drive American healthcare costs.

Why It Matters

Cost and access shape oncology care daily; this explains the system you operate in.

One Move

Identify one cost dynamic from the book that you see in oncology.

Essentials · Book

The immune system, told through four human stories — the basis of immuno-oncology.

The Big Idea

Richtel explains immunity through patients' lives, making a complex system human and clear.

Why It Matters

Immunotherapy is central to modern oncology; this is the most readable way to truly get the immune system.

One Move

Map one immunotherapy you encounter to the immune mechanism behind it.

Essentials · Book

The classic on actually running your own lab.

The Big Idea

Barker's hands-on guide to the management side of leading a research group.

Why It Matters

New oncology PIs are great scientists and untrained managers; this fills that gap.

One Move

Identify one lab-management habit to put in place before your team grows.

Essentials · Book

A critical look at how evidence and industry can go wrong.

The Big Idea

Goldacre exposes problems in trials, publication, and marketing that distort medicine.

Why It Matters

Knowing the field's failure modes makes you a more rigorous, trustworthy oncology professional.

One Move

Pick one of Goldacre's critiques and check whether it shows up in your work.

Essentials · Book

Board-certified oncology pharmacist exam prep.

The Big Idea

A focused study resource for the BCOP certification.

Why It Matters

BCOP certification advances oncology pharmacy careers; this is the prep path.

One Move

Take a practice section and identify your two weakest domains.

Essentials · Book

How to stand out in a crowded MSL pool — and become the obvious hire.

The Big Idea

A focused guide to differentiating yourself as an MSL candidate: positioning, preparation, and the signals that move you to the top of the stack.

Why It Matters

MSL roles draw deep pools of qualified PharmDs, PhDs and MDs. The science gets you considered; differentiation gets you hired — and in oncology, that edge matters most.

One Move

Rewrite your one-line summary so it leads with the therapeutic-area value you bring, not your degree.

Essentials · Book

Serious illness and what matters at the end — essential across cancer care.

The Big Idea

Gawande examines how medicine handles aging and dying, and how it could do better.

Why It Matters

Every oncology professional confronts mortality; this reshapes how you think about care and goals.

One Move

Reflect on one way your work could better honor what matters to patients.

Essentials · Book

A young survivor's memoir of illness and the hard road back to life.

The Big Idea

Jaouad's account of leukemia, survival, and rebuilding afterward.

Why It Matters

Survivorship is an under-seen part of the oncology journey; this gives it a voice.

One Move

Consider how your work touches the "after" of treatment, not just the treatment.

Essentials · Book

Win by making the competition irrelevant — not fighting over the same space.

The Big Idea

The authors' method for creating uncontested markets instead of bloody ones.

Why It Matters

Crowded oncology categories reward those who find uncontested space — a new indication, model, or audience.

One Move

Map where everyone competes in your area, then ask what no one is offering.

Essentials · Book

Brand strategy for pharma and medtech, demystified.

The Big Idea

Smith's accessible take on building and managing health-product brands.

Why It Matters

Commercial and marketing roles in oncology run on brand thinking; this is a clear entry.

One Move

Articulate the core brand promise of a product you work on.

Essentials · Book

A genetic disease and the science that changed its course.

The Big Idea

Trivedi tells the cystic-fibrosis story — from gene to transformative therapy.

Why It Matters

A model for how genomic understanding becomes targeted therapy — oncology's own trajectory.

One Move

Draw one parallel between the CF story and a targeted oncology therapy.

Essentials · Book

A map of industry roles — and how real people landed them.

The Big Idea

Freedman surveys the full range of biotech/pharma jobs across discovery, clinical, regulatory, and commercial.

Why It Matters

If you're eyeing industry from academia or clinic, this shows what's out there and how to get in.

One Move

Circle three roles you didn't know existed and one you'd want to learn more about.

Essentials · Book

The ONS standard for safe chemo and immunotherapy practice.

The Big Idea

The authoritative ONS reference on safe administration and management.

Why It Matters

Safe practice is non-negotiable in oncology nursing; this is the standard of record.

One Move

Review one guideline relevant to a regimen you handle.

Essentials · Book

An approachable primer on the statistics behind trials and evidence.

The Big Idea

A famously readable introduction to biostatistics and epidemiology.

Why It Matters

Oncology professionals constantly read trial stats; this demystifies them without a stats degree.

One Move

Learn what a hazard ratio really means, then re-read one trial's results.

Essentials · Book

The standard working guide to drug safety and pharmacovigilance.

The Big Idea

Cobert covers the practical world of monitoring and reporting drug safety.

Why It Matters

Pharmacovigilance is a stable, meaningful oncology path — patient safety as a profession.

One Move

Learn what an adverse-event signal is and how it's acted on.

Essentials · Book

The definitive resource for oncology nursing practice and certification.

The Big Idea

The ONS core reference covering the breadth of oncology nursing.

Why It Matters

For oncology nurses, this is the foundation — and the OCN certification backbone.

One Move

Identify the one practice area you'd most like to deepen, and start there.

Essentials · Book

Make better decisions by beating the biases that wreck them.

The Big Idea

The Heaths' WRAP process: widen options, reality-test assumptions, attain distance, prepare to be wrong.

Why It Matters

High-stakes oncology decisions deserve a process, not just a gut call.

One Move

Generate one more real option before locking in your next big decision.

Essentials · Book

How AI can make healthcare more human — oncology's data future.

The Big Idea

Topol explores how AI could transform diagnosis, treatment, and the clinician's role.

Why It Matters

AI is entering oncology fast; this frames the opportunity and the human stakes.

One Move

Note one task in your work AI could plausibly augment in the next few years.

Essentials · Book

The definitive clinical-oncology reference text.

The Big Idea

The comprehensive standard reference across cancer types and treatment.

Why It Matters

For oncologists and fellows, this is the field's bible.

One Move

Use it to go one level deeper on a tumor type you see often.

Essentials · Book

The Sacklers, opioids, and a hard look at the industry's incentives.

The Big Idea

Keefe's investigation of the family and company behind the opioid crisis.

Why It Matters

Every pharma professional should grapple with the industry's ethical failures; this is the cautionary text.

One Move

Name one guardrail in your own work that exists to prevent this kind of harm.

Essentials · Book

Why so many medical practices get reversed — and how to avoid building on sand.

The Big Idea

The authors examine how practices adopted without solid evidence later get overturned.

Why It Matters

Oncology adopts fast; understanding reversal makes you a more careful interpreter of new data.

One Move

Identify one practice you assume is settled and check the evidence behind it.

Essentials · Book

Once you're in the seat — how to actually be great at the job.

The Big Idea

A practical guide to the craft of the role: KOL engagement, scientific exchange, and the field activities that define a strong MSL.

Why It Matters

Landing the role is half the battle; the MSLs who get promoted master KOL relationships and scientific exchange early. In oncology's KOL-dense landscape, that compounds fast.

One Move

Write the one scientific question you genuinely want a KOL's view on before your next meeting — and lead with it.

Essentials · Book

The high-stakes inside story of building a blockbuster cancer drug.

The Big Idea

Vardi chronicles the race, money, and people behind a breakthrough oncology therapy.

Why It Matters

It shows how oncology drugs actually get made and commercialized — the business reality behind the science.

One Move

Note one thing the story teaches about how science becomes a product.

Essentials · Book

Drug process development and manufacturing, made accessible.

The Big Idea

Harrison explains how a molecule scales from lab to commercial production.

Why It Matters

CMC and manufacturing are under-appreciated oncology career tracks; this opens the door.

One Move

Learn one reason scaling up a process is harder than it sounds.

Essentials · Book

The classic on how clinical trials are designed and conducted.

The Big Idea

The standard reference on trial design, conduct, analysis, and interpretation.

Why It Matters

Trials are the engine of oncology evidence; understanding their design makes you sharper.

One Move

Learn superiority vs. non-inferiority designs, then spot one in a recent oncology trial.

Essentials · Book

Value, pricing, and reimbursement across global health systems.

The Big Idea

A primer on how drugs get paid for — HTA, pricing, and access strategy.

Why It Matters

Market access decides whether a great oncology drug reaches patients; it's a fast-growing track.

One Move

Learn how one oncology drug is reimbursed in one market you care about.

Essentials · Book

How the first biotech was built, where science met venture capital.

The Big Idea

Hughes documents Genentech's founding and the birth of the biotech industry.

Why It Matters

Understanding biotech's origins helps you read today's industry — useful for BD, strategy, or the curious.

One Move

Note one lesson from Genentech's founding relevant to today's oncology biotech.

Essentials · Book

How genetics and genomics shape modern medicine.

The Big Idea

A clear textbook connecting genomic science to clinical practice.

Why It Matters

Precision oncology runs on genomics; this is the grounding for diagnostics and biomarker work.

One Move

Learn how one biomarker test guides an oncology treatment decision.

Essentials · Book

What real strategy looks like — and how to spot the fluff.

The Big Idea

Rumelt strips strategy down to diagnosis, a guiding policy, and coherent action.

Why It Matters

Oncology plans are often goals dressed as strategy; this teaches the difference.

One Move

Test one current "strategy": does it have a clear diagnosis and coherent actions?

Essentials · Book

A practical guide for new investigators starting their labs.

The Big Idea

A widely used handbook on launching and managing an academic research career.

Why It Matters

For early oncology investigators, it's a trusted, free-to-find roadmap.

One Move

Pick one chapter matching your current challenge and act on it.

Essentials · Book

A provocative critique of oncology trials, evidence, and value.

The Big Idea

Prasad challenges how cancer drugs are tested, approved, and priced.

Why It Matters

It sharpens your critical eye on the very evidence oncology runs on — uncomfortable but essential.

One Move

Pick one of Prasad's critiques and decide whether you agree.

Essentials · Book

For nurses navigating the clinical-trial world — the OCRN role.

The Big Idea

An ONS guide to the specialized role of the oncology clinical research nurse.

Why It Matters

Clinical research nursing is a growing oncology niche bridging care and trials.

One Move

Decide whether the research-nurse path fits your interests.

Essentials · Book

A portable clinical-oncology handbook for the day-to-day.

The Big Idea

A concise, practical bedside reference for clinical oncology.

Why It Matters

The everyday companion to the big reference — fast answers in clinic.

One Move

Keep it handy and use it on your next tricky case.

Essentials · Book

The field's first unified playbook for Medical Affairs as a career — from 80+ leaders.

The Big Idea

A comprehensive, multi-author reference on what Medical Affairs is, what each function within it does, and where the field is heading.

Why It Matters

Medical Affairs is now a third strategic pillar alongside R&D and Commercial, but few people grasp its full shape. If you're building a career anywhere in MA, this is the map.

One Move

Skim the contents and flag two MA functions you didn't know existed but could see yourself in.

Essentials · Book

The go-to framework for pharma marketing planning.

The Big Idea

Smith's structured approach to building rigorous pharma marketing plans.

Why It Matters

For oncology marketers, this is the discipline behind a credible plan.

One Move

Draft a one-page skeleton plan for a product using Smith's structure.

Essentials · Book

How Medical Affairs creates value across pharma and medtech — and proves it.

The Big Idea

A structured look at how MA functions operate and demonstrate their value across the product lifecycle.

Why It Matters

As MA fights for budget and headcount, the people who can articulate the function's value are the ones who rise — useful whether you're in MA or aiming for it.

One Move

Write one interview-ready sentence, in your own words, on how MA creates value.

Essentials · Book

Paul Farmer and the fight for global health equity.

The Big Idea

Kidder's portrait of Farmer's mission to bring care to the world's poorest.

Why It Matters

Global oncology disparities are vast; this is the inspiration for caring about access everywhere.

One Move

Learn one fact about cancer-care access in a low-resource setting.

Essentials · Book

The classic plain-English map of the FDA drug-approval process.

The Big Idea

Mathieu walks through how drugs get from IND to approval.

Why It Matters

Understanding the approval path clarifies timelines and decisions across every oncology function.

One Move

Trace one oncology drug you know through the approval stages Mathieu describes.

Essentials · Book

Industry marketing strategy, taught through real cases.

The Big Idea

A foundational text pairing marketing strategy with pharma case studies.

Why It Matters

Cases make abstract strategy concrete — useful for anyone in or aiming at oncology commercial.

One Move

Pick one case and note what you'd have done differently.

Essentials · Book

An accessible on-ramp into regulatory affairs for scientists changing lanes.

The Big Idea

Harrison introduces regulatory concepts for those moving from the bench.

Why It Matters

For scientists eyeing a regulatory pivot, this is the gentle, practical entry point.

One Move

Decide whether regulatory's mix of science and process actually fits you.

Essentials · Book

The foundational reference on the psychological care of cancer patients.

The Big Idea

The field-defining text on psycho-oncology, founded by Holland.

Why It Matters

The emotional dimension of cancer is real care, not a soft add-on; this is the discipline's anchor.

One Move

Learn one psycho-oncology concept you can apply in patient interactions.

Essentials · Book

The field-standard reference for regulatory professionals.

The Big Idea

The RAPS series covers the core knowledge of drug and device regulation.

Why It Matters

Regulatory is a major oncology career track; this is the recognized foundation.

One Move

Skim the contents and identify the regulatory area you'd most want to specialize in.

Essentials · Book

A reference covering manufacturing controls and regulatory filings.

The Big Idea

A comprehensive text on regulatory and quality across the product lifecycle.

Why It Matters

Quality and CMC roles intersect regulation constantly; this connects the two.

One Move

Note how a manufacturing change triggers regulatory work.

Essentials · Book

Essential knowledge for life scientists making the jump to industry.

The Big Idea

Harrison's accessible orientation to how pharma works for newcomers from academia.

Why It Matters

The academia-to-industry leap is one of oncology's most common pivots; this smooths the landing.

One Move

List the three industry basics you're least sure about and read those sections first.

Essentials · Book

Predictive, data-rich, personalized medicine — where care is heading.

The Big Idea

Hood and Price argue for a shift to proactive, data-driven health.

Why It Matters

Precision and prevention are reshaping oncology; this frames the data-first future.

One Move

Note one way proactive data could change early cancer detection in your area.

Essentials · Book

How people find — and lose — hope through illness.

The Big Idea

Groopman, an oncologist, explores the role of hope in facing disease.

Why It Matters

Hope is part of oncology care; this examines it honestly, without false cheer.

One Move

Reflect on how you talk about hope with patients — and whether it's honest.

Essentials · Book

Drug discovery and biotech-startup life, up close.

The Big Idea

Werth's classic account of Vertex's early years and the gamble of drug discovery.

Why It Matters

For anyone curious about biotech, this captures the obsession, risk, and grind of making a new medicine.

One Move

Decide whether the startup-science life appeals to you — and why.

Essentials · Book

Living fully while dying of cancer — a luminous memoir.

The Big Idea

Riggs writes about finding meaning and ordinary joy in terminal illness.

Why It Matters

It deepens empathy for what patients carry day to day.

One Move

Carry one of Riggs's reflections into your next patient or family interaction.

Essentials · Book

Why checklists save lives in complex, high-stakes work.

The Big Idea

Gawande shows how simple checklists prevent catastrophic errors in medicine and beyond.

Why It Matters

Oncology's complexity is exactly where checklists prevent harm — for clinicians and quality roles alike.

One Move

Build a short checklist for one error-prone task you do regularly.

Essentials · Book

Jennifer Doudna, CRISPR, and the gene-editing revolution.

The Big Idea

Isaacson's biography of Doudna and the race to harness CRISPR.

Why It Matters

Gene editing is moving into oncology fast; this is the accessible inside story of how it arrived.

One Move

Identify one way gene editing could touch your area in the next five years.

Essentials · Book

A practical handbook for understanding the clinical-research industry.

The Big Idea

An accessible guide to how clinical trials are designed, run, and managed.

Why It Matters

Clinical operations and research roles are oncology mainstays; this is a grounding for entrants.

One Move

Map the trial lifecycle and note where your interest or role sits.

Essentials · Book

A pioneer's history of the war on cancer — and where it's headed.

The Big Idea

DeVita, a chemotherapy pioneer, recounts the fight against cancer and the system's flaws.

Why It Matters

From one of the field's architects, this is insider context on how oncology got here and what still blocks progress.

One Move

Note one systemic barrier DeVita names that you recognize in your own work.

Essentials · Book

Concept to launch — the whole drug journey, concisely.

The Big Idea

Harrison gives a clear overview of how a molecule becomes a medicine.

Why It Matters

Whatever function you're in, seeing the full pipeline helps you understand where your work fits.

One Move

Locate your role on the development cycle and note who's upstream and downstream of you.

Essentials · Book

Anticancer drugs, dosing, and toxicities — explained simply.

The Big Idea

A straightforward reference to oncology pharmacology.

Why It Matters

A clear pharmacology grounding serves pharmacists, nurses, and MSLs alike.

One Move

Review the mechanism and key toxicities of one drug class you encounter.

Essentials · Book

The Pulitzer-winning "biography of cancer" — essential context for everyone in oncology.

The Big Idea

Mukherjee traces cancer from ancient times to modern medicine in a sweeping narrative.

Why It Matters

Whatever your role, this is the shared story of the disease you work on — the context that makes the work make sense.

One Move

Read the prologue this week; it reframes why the field exists.

Essentials · Book

The story of heredity — from Mendel's peas to the gene-editing era.

The Big Idea

Mukherjee tells the history and science of the gene and its power over life and medicine.

Why It Matters

Genomics now drives oncology; this gives the deep context behind targeted therapy and precision medicine.

One Move

Note one way the gene's story connects to a therapy you work on or near.

Essentials · Book

A practical road map to writing fundable research grants.

The Big Idea

Lai gives a step-by-step system for planning and writing competitive grants.

Why It Matters

Funding is the lifeblood of oncology research careers; grant skill is career-defining.

One Move

Draft one specific aim for a project using Lai's structure.

Essentials · Book

The HeLa story — a touchstone on consent, ethics, and the people behind the science.

The Big Idea

Skloot tells the story of Henrietta Lacks, whose cells transformed research without her knowledge.

Why It Matters

Research ethics and patient dignity sit at oncology's core; this is the human reminder behind the cell line.

One Move

Reflect on one place your work touches patient consent or data — and whether it honors the person.

Essentials · Book

Why great organizations get disrupted — and how not to.

The Big Idea

Christensen's theory of disruptive innovation and why incumbents miss it.

Why It Matters

Oncology is being disrupted — new modalities, diagnostics, AI; this helps you see what's coming.

One Move

Ask what "good enough but cheaper/simpler" innovation could upend your corner of oncology.

Essentials · Book

Personalized medicine, explained by the man who mapped the genome.

The Big Idea

Collins shows how genomics is reshaping prevention, diagnosis, and treatment.

Why It Matters

Precision oncology is the present, not the future; this grounds the personalized-medicine promise.

One Move

Note one place precision medicine is changing practice in your corner of oncology.

Essentials · Book

Build-measure-learn — how to launch the new without betting it all.

The Big Idea

Ries' method of validated learning, MVPs, and fast iteration for new ventures.

Why It Matters

Biotech founders and intrapreneurs in oncology can test ideas cheaply before scaling.

One Move

Define the smallest experiment that would test your riskiest assumption.

Essentials · Book

The step-by-step on breaking into the MSL role — from the chair of the MSL Society.

The Big Idea

Dyer lays out exactly what hiring managers look for in MSL candidates, and how to build and present that profile — from networking to the interview.

Why It Matters

"How do I become an MSL?" is the single most-asked question in oncology careers — and the bar is competency-based, not just your degree. The most direct roadmap there is.

One Move

Map your experience against Dyer's MSL competency list and circle the two biggest gaps to close this quarter.

Essentials · Book

A plain-English tour of what the MSL role actually is — for anyone weighing the move.

The Big Idea

Albert walks the role end to end — what the job involves day to day, who it suits, and how it fits inside Medical Affairs.

Why It Matters

Plenty of oncology clinicians and scientists are MSL-curious but don't actually know what the role entails. This answers that before you spend months chasing it.

One Move

Write one honest sentence on whether the day-to-day genuinely fits you — and why.

Essentials · Book

Digital medicine and the rise of the empowered patient.

The Big Idea

Topol argues data and devices are shifting power toward patients.

Why It Matters

Oncology patients are more informed and connected than ever; this reframes the relationship.

One Move

Consider one way your work could better serve a more empowered patient.

Essentials · Book

Healthcare costs, hidden prices, and the push for transparency.

The Big Idea

Makary investigates the money games in healthcare and the movement to fix them.

Why It Matters

Oncology is among the costliest care; understanding pricing makes you a better advocate.

One Move

Find out the real cost of one thing you order or recommend.

Essentials · Book

Why launches succeed or fail — from someone who's run them.

The Big Idea

O'Neill distills the factors that make or break a pharmaceutical launch.

Why It Matters

Launches are make-or-break in oncology commercial careers; this is the practical playbook.

One Move

Name one launch factor O'Neill flags that you could influence in your role.

Essentials · Book

Cell biology as story — the foundation under all of modern medicine.

The Big Idea

Mukherjee explores the cell, from discovery to cell therapies, in narrative form.

Why It Matters

Cell and gene therapies are reshaping oncology; this grounds you in the biology behind the breakthroughs.

One Move

Pick one cell-therapy concept you half-understand and let this fill it in.

Essentials · Book

A landmark memoir of grief and loss.

The Big Idea

Didion's unflinching account of the year after her husband's sudden death.

Why It Matters

Grief surrounds oncology; understanding it makes you more present for patients and families.

One Move

Notice one way grief shows up in your work that you usually move past.

Essentials · Book

A neurosurgeon's reflection on living and dying, written as he faced cancer.

The Big Idea

Kalanithi's memoir of facing terminal illness as both doctor and patient.

Why It Matters

It puts you in the patient's chair — a perspective every oncology professional needs.

One Move

Note one assumption about patients this book changes for you.

Essentials · Book

Building something genuinely new — not just copying what works.

The Big Idea

Thiel on creating breakthrough (0 to 1) value rather than incremental (1 to n) improvement.

Why It Matters

Oncology's biggest wins come from true novelty; this challenges how you think about moats.

One Move

Ask what important truth about your field few people agree with you on.

Essentials · Episode

How to actually capture and share MSL insights that matter — the full cycle, demystified.

The Big Idea

Patrina Pellett and Richard Swank walk Tom Caravela through the MSL insight cycle — from gathering to sharing — covering common mistakes, competitive intelligence, and the myths that trip teams up.

Why It Matters

Insights are a core MSL deliverable in oncology, but poorly captured ones get ignored. Mastering the cycle makes your field intelligence genuinely useful.

One Move

Capture your next field insight with your audience in mind — what would make a decision-maker act on it?

Essentials · Episode

Why business acumen is the MSL's other essential currency — beyond the science.

The Big Idea

Maria Abunto and Nabhan Islam explore with Tom Caravela the role of business acumen in medical affairs — defining it, mastering the language, and demonstrating it as an MSL.

Why It Matters

Scientific skill alone plateaus an oncology MSL career; business acumen is what earns a seat at the strategy table.

One Move

Learn one piece of your company's commercial strategy well enough to connect your field work to it.

Essentials · Episode

The compliance gray areas every MSL needs to navigate confidently.

The Big Idea

Jessica McLin and Melody Davis explore with Tom Caravela common compliance issues for MSLs — FDA standards, ethical collaboration with sales, and the importance of knowing your company SOPs.

Why It Matters

Compliance missteps can end an oncology field career; knowing the common gray areas keeps you safe and effective.

One Move

Review one company SOP you're shaky on before your next ambiguous KOL or sales interaction.

Essentials · Episode

How to move from diagnostics into pharma as an MSL.

The Big Idea

Namratha Sastry shares with Tom Caravela her journey from diagnostics to pharma — the networking that drove it, the regulatory differences, and how KOL and commercial interactions compare.

Why It Matters

For oncology professionals in diagnostics, the move to pharma is a real path; this maps the differences to expect.

One Move

Learn one key regulatory difference between diagnostics and pharma before interviewing across the two.

Essentials · Episode

How MSLs work effectively with commercial — without crossing compliance lines.

The Big Idea

Rob Rosti helps Tom Caravela map the MSL-commercial relationship: the distinct roles, effective communication, and how to handle compliance challenges and non-compliant requests.

Why It Matters

The MSL-commercial boundary is delicate and high-stakes in oncology; navigating it well protects both your impact and your compliance standing.

One Move

Clarify one boundary with a commercial counterpart before it becomes a compliance gray area.

Essentials · Episode

How MSLs bring real value — and when in development they bring it most.

The Big Idea

Steven Stein of Arena Pharmaceuticals explores with Tom Caravela the value of the MSL role — early KOL engagement, strategic timing in drug development, and overcoming internal challenges.

Why It Matters

Oncology MSLs add the most value when engaged early and strategically; understanding this elevates how you position the role.

One Move

Identify one way to demonstrate your value earlier in your therapy's development cycle.

Essentials · Episode

When should MSLs get involved in drug development? Earlier than you think.

The Big Idea

Jeff Vaughn and Dean McAllister explore with Tom Caravela the timing of MSL involvement in drug development — debunking misconceptions and showing the value of early engagement.

Why It Matters

Early MSL involvement adds strategic value in oncology development; knowing the right timing elevates the role.

One Move

Identify one development stage where MSL input could add value earlier than it currently does.

Essentials · Episode

How MSLs can use real-world evidence to deepen their scientific impact.

The Big Idea

Elizabeth Pash shares with Tom Caravela how MSLs leverage real-world evidence — increasingly accepted since the 21st Century Cures Act — to enrich understanding beyond clinical trials.

Why It Matters

RWE is reshaping oncology evidence; MSLs fluent in it bring more to KOL conversations and medical strategy.

One Move

Learn one real-world evidence study in your therapeutic area well enough to discuss it with a KOL.

Essentials · Episode

How market access intersects with the MSL role — and why it matters.

The Big Idea

Ruchit Parikh shares with Tom Caravela the role of market access in pharma — how it intersects with MSL work, common knowledge gaps, and resources to close them.

Why It Matters

Market access shapes whether oncology therapies reach patients; MSLs who understand it bring more to the table.

One Move

Learn the basics of how your therapy gets reimbursed, so you can speak to access when it comes up.

Essentials · Episode

How breaking down silos — and elevating the patient voice — is reshaping oncology drug development.

The Big Idea

Dr. Ramin Farhood and Dr. Kirk Shepard, co-authors of "Voices of Oncology," share with host Joe Pardavila how breaking silos and bringing every perspective to the table is reshaping oncology drug development.

Why It Matters

Silos slow oncology progress; this lays out the collaboration-first philosophy at the heart of the Oncology Voices Network.

One Move

Identify one silo in your work, and take one step to bring a missing perspective to the table.

Essentials · Episode

How the MSL role differs in Canada vs. the US — territories, regulators, and logistics.

The Big Idea

Claudia Barube and Jeffrey Vaughn explore with Tom Caravela the Canadian MSL experience — differing responsibilities and territories, working with Health Canada, and language and logistical realities.

Why It Matters

For oncology MSLs considering or working in Canada, understanding the differences from the US market is essential to navigating it well.

One Move

Learn one key regulatory or logistical difference for each market you cover.

Essentials · Episode

How non-traditional KOL engagement opens doors traditional outreach can't.

The Big Idea

Lindsey Harrer explores with Tom Caravela non-traditional KOL engagement — aligning MSL objectives with KOL needs, personalized communication, and the compliance challenges involved.

Why It Matters

As traditional KOL access tightens in oncology, non-traditional engagement becomes a real edge — done compliantly.

One Move

Identify one non-traditional way to add value to a KOL relationship, and check it against compliance first.

Essentials · Episode

The MSL is shifting from scientific expert to strategic adviser — here's the difference.

The Big Idea

Joy Morrell explores with Tom Caravela the dual nature of the MSL role — scientific expertise plus the soft skills and active listening that make an MSL a strategic adviser.

Why It Matters

Top oncology MSLs are strategic advisers, not just data experts; understanding the shift helps you grow into it.

One Move

Lead with a question and listen in your next KOL meeting — practice being the strategic adviser, not the lecturer.

Essentials · Article

The biggest near-term AI wins in pharma may be in medical affairs — if humans stay in control.

The Big Idea

McKinsey highlights medical affairs as one of the most promising areas for generative AI in pharma, estimating multi-billion-dollar efficiency gains. Concrete use cases: large language models can synthesize insights from thousands of MSL-KOL interactions (today MSLs analyze only a tiny fraction of their notes), and gen-AI tools trained on approved content can rapidly assemble tailored materials for specific stakeholders — potentially multiplying engagement — while every output passes medical-legal-regulatory review.

Why It Matters

For oncology medical-affairs teams drowning in literature and interaction notes, AI that surfaces insights and drafts tailored content frees scarce expert time for the high-value scientific exchange that matters most.

One Move

Pilot one AI use case — drafting a medical-information response or summarizing KOL notes — with MLR review built in.

Essentials · Episode

How collaboration accelerates cancer cures — from the creator of the Oncology Voices Network.

The Big Idea

Dr. Kirk Shepard shares with Michael Pietrack the mission behind the Oncology Voices Network and "Voices of Oncology" — how uniting cross-functional stakeholders accelerates cancer drug development.

Why It Matters

Collaboration across oncology functions is what speeds therapies to patients; this is the vision behind OVN itself.

One Move

Identify one cross-functional partner whose collaboration could accelerate your current work.

Essentials · Book

Stop managing everyone else's reactions and reclaim your focus.

The Big Idea

Robbins' mindset tool: let people do what they'll do, and put your energy where you have control.

Why It Matters

Oncology is full of things you can't control — people, politics, outcomes; this frees energy for what you can.

One Move

Name one thing you're trying to control that you should "let them" handle — and release it.

Essentials · Episode

What the diagnostic MSL role is — and how it compares to the therapeutic MSL.

The Big Idea

Keith Fairall explores with Tom Caravela the diagnostic MSL role — its distinctions from the therapeutic MSL, the commercial-team dynamics, and the metrics that define success.

Why It Matters

Diagnostics is a growing oncology space; the diagnostic MSL is an under-known path with real opportunity.

One Move

Explore how the diagnostic MSL role differs from the therapeutic one — it may be an opening you've overlooked.

Essentials · Article

Bringing Medical Affairs in early — not late — can redefine the whole drug-development journey.

The Big Idea

SSI Strategy argues for integrating Medical Affairs from the outset of drug development: a cross-functional team structure, an evidence-generation plan beyond regulatory requirements, early KOL relationships to inform study design, and a scientific communication strategy that builds credibility.

Why It Matters

In oncology, where data and KOL trust decide a therapy's reception, embedding Medical Affairs early is a strategic-leadership move that shapes the entire program.

One Move

Identify one place in your program where Medical Affairs is engaged too late, and propose bringing it in earlier.

Essentials · Episode

What a Thought Leader Liaison does — and how it differs from the MSL.

The Big Idea

Jim Hahn of EMD Serono explains to Tom Caravela the Thought Leader Liaison role — building strategic KOL relationships to align commercial objectives, typically from a sales background.

Why It Matters

The TLL is a distinct oncology career path adjacent to the MSL; knowing the difference helps you choose or navigate it.

One Move

Learn how the TLL and MSL roles differ at your company, and which fits your strengths.

Essentials · Episode

What managed care MSLs do — and why the role is distinct.

The Big Idea

Todd Wandstrat shares with Tom Caravela the world of managed care MSLs — the history of health plans, PBMs, and integrated networks, and the unique customer base these MSLs serve.

Why It Matters

Managed care is an under-known MSL path; for oncology professionals, it's a distinct route worth understanding.

One Move

Learn how managed care MSLs differ from field MSLs, and whether the path fits your interests.

Essentials · Episode

How commercial leadership and clear communication shape oncology success — and why patients depend on it.

The Big Idea

This episode explores how commercial leadership, cross-functional collaboration, and clear communication drive success in oncology — ultimately affecting the patients who depend on it.

Why It Matters

Commercial roles in oncology carry real patient stakes; seeing that link elevates how commercial professionals lead and communicate.

One Move

Connect one commercial decision you're working on back to its patient impact, and lead with that framing.

Essentials · Article

Representative enrollment isn't only equity — it's scientific rigor.

The Big Idea

Diverse, representative enrollment isn't only an equity goal — it's a scientific one. Inclusive trials improve the generalizability of findings, build trust in the results, and make it possible to detect treatment-response differences across subgroups, which is central to precision oncology. Yet cancer-trial participants still skew disproportionately white, younger, and healthier than the patient population, which is why the FDA now asks for Diversity Action Plans in pivotal trials.

Why It Matters

For everyone in oncology drug development, championing representative trials directly improves the quality and reach of the medicines being studied — diversity and rigor are the same goal here.

One Move

Champion broader eligibility and representative enrollment in the next trial or insight discussion you touch.

All Essentials shelves